SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Dynavax Technologies Corporation and Novavax, Inc. over the past decade. From 2014 to 2023, Dynavax's SG&A expenses grew by approximately 760%, while Novavax saw an astonishing increase of over 2,250%.

Dynavax Technologies Corporation

Dynavax started with a modest SG&A expense of $17.8 million in 2014, which surged to $152.9 million by 2023. This growth reflects their strategic investments in marketing and administration to support their expanding product portfolio.

Novavax, Inc.

Novavax, on the other hand, experienced a dramatic rise from $19.9 million in 2014 to $468.9 million in 2023. This spike is indicative of their aggressive push in the vaccine market, especially during the COVID-19 pandemic.

Both companies illustrate different strategies in managing SG&A expenses, offering insights into their operational priorities and market positioning.